Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
92%
Obesity
90%
Bariatric Surgery
56%
Proton Density Fat Fraction
53%
Lifestyle Modification
52%
Metabolic Syndrome
52%
Iron Corrected T1
47%
Pancreatic Steatosis
47%
Liver Biopsy
36%
Laparoscopic Sleeve Gastrectomy
33%
Insulin Resistance
29%
Visceral Adipose Tissue
28%
Fatty Pancreas
28%
Ultrasound
27%
Lifestyle Modification Program
25%
Nonalcoholic Fatty Pancreas Disease (NAFPD)
24%
Machine Learning in Medical Imaging
23%
Subcutaneous Adipose Tissue
23%
Beige Adipocytes
23%
Deep Learning
23%
Adipose Tissue
23%
Obesity-related Diseases
23%
MR Spectroscopy
23%
Metabolic Disease
23%
Nonalcoholic Steatohepatitis
23%
Functional Syndromes
23%
Disease Correlation
23%
Weight Control
23%
Metabolic Dysfunction-associated Steatohepatitis
23%
Ultrasound Liver
23%
Liver Attenuation
23%
T1 Mapping
23%
White Fat Browning
23%
Potential Biomarkers
23%
Brown Fat
23%
MRI Evaluation
23%
Brown Adipose Tissue
23%
Clinical Impact
23%
Mesenteric Fat Thickness
23%
Liver Steatosis
23%
Gamma-glutamyltransferase
23%
Prospective Cohort Study
23%
Chinese Adolescents
23%
β-cell Dysfunction
23%
Imaging Methods
23%
Attenuation Imaging
23%
Remission
19%
Tissue Activation
16%
Pancreatic Fat
15%
Type 2 Diabetes Mellitus (T2DM)
15%
Medicine and Dentistry
Magnetic Resonance Imaging
100%
Nonalcoholic Fatty Liver
92%
Lifestyle Modification
62%
Bariatric Surgery
57%
Metabolic Syndrome
53%
Steatosis
53%
Iron
47%
Fatty Liver
46%
Biological Marker
41%
Liver Biopsy
36%
Laparoscopic Sleeve Gastrectomy
34%
Insulin Resistance
29%
Proton Nuclear Magnetic Resonance
25%
Beta Cell
23%
Brown Adipose Tissue
23%
White Adipose Tissue
23%
Gamma-Glutamyl Transpeptidase
23%
Mesenteric Fat
23%
Steatohepatitis
23%
Prospective Cohort Study
23%
Body Mass Index
14%
Type 2 Diabetes
11%
Patient with Obesity
10%
Diabetes
10%
Adipose Tissue
9%
Morbid Obesity
8%
Abdominal Fat
7%
Comorbidity
7%
Anthropometry
7%
Odds Ratio
7%
Metabolic Dysfunction-Associated Steatotic Liver Disease
6%
Diagnostic Accuracy
6%
Disease Activity
6%
Diagnostic Performance
5%
Non-Alcoholic Fatty Liver Disease
5%